CLOZARIL

LOE Approaching

clozapine

NDAORALTABLETPriority Review
Approved
Sep 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14

Mechanism of Action

unknown. However, it has been proposed that the therapeutic efficacy of clozapine in schizophrenia is mediated through antagonism of the dopamine type 2 (D 2 ) and the serotonin type 2A (5-HT 2A ) receptors. CLOZARIL also acts as an antagonist at adrenergic, cholinergic, histaminergic and other…

Pharmacologic Class:

Atypical Antipsychotic

Clinical Trials (5)

NCT00395915Phase 4Unknown

Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia

Started Sep 2006
106 enrolled
Schizophrenia
NCT00328367Phase 4Completed

Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia

Started Dec 2005
61 enrolled
Schizophrenia
NCT00250575Phase 3Completed

A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia

Started Nov 2005
43 enrolled
Schizophrenia
NCT00216281Phase 3Terminated

Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia

Started Sep 2005
126 enrolled
Schizophrenia
NCT00176436Phase 4Completed

Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients

Started Feb 2004
40 enrolled
Schizophrenia